Investors Continue to Support Breakthrough Research on Infant Gut Health
Evolve s final round of funding will help further the brand s goal of resolving Newborn Gut Deficiency in the U.S.
News provided by
Share this article
DAVIS, Calif., May 25, 2021 /PRNewswire/
Evolve BioSystems, Inc., a privately-held leading microbiome company, announced today the second and final close of its Series D round of funding exceeding $65 million, led by investors Cargill and Manna Tree. Oversubscribed from original expectations, this second closing of the Series D will accelerate the company s mission to research and address Newborn Gut Deficiency (NGD), a dramatic shortage of key good bacteria in the infant gut microbiome, and thus improve the health of infants worldwide.
Dairy Dialog podcast 121: Tate & Lyle, Evolve Biosystems, Bridge Cheese
Dairy Dialog podcast 121: Tate & Lyle, Evolve Biosystems, Bridge Cheese This week we feature three interviews, with five guests. We have conversations with Timothy Brown, CEO of Evolve BioSystems and Pam Shepherd, managing director of Manna Tree; Jim Carr, PhD, director, sweeteners global ingredient technology and Abigail Storms, vice president of sweetener innovation at Tate & Lyle; and Michael Harte, managing director of Bridge Cheese. We also have our weekly look at the global dairy markets with Charlie Hyland at StoneX.
Evolve BioSystems announces investment from Cargill and Manna Tree for infant gut health probiotic
Evolve BioSystems announces investment from Cargill and Manna Tree for infant gut health probiotic US microbiome company Evolve BioSystems has announced that it completed a first close in a $55m Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health.
The new capital will be used to help the company continue commercializing a next generation of probiotic capable of addressing a widespread deficiency in the infant gut microbiome. We are thrilled to announce our newest investors as we continue our quest to address this health crisis in newborns, said Timothy Brown, CEO of Evolve BioSystems.
Evolve BioSystems Announces Major Strategic Investment from Cargill and Manna Tree to Support Innovative Probiotic That Dramatically Improves Infant Gut Health
Evolve s innovative probiotic addresses widespread Newborn Gut Deficiency by restoring key bacteria in the infant gut microbiome
News provided by
Share this article
Share this article
DAVIS, Calif., Feb. 8, 2021 /PRNewswire/ Evolve BioSystems announced today that it completed a substantial first close in a $55 million Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health. The new capital will be used to help the company continue commercializing a next generation of probiotic capable of addressing a widespread deficiency in the infant gut microbiome.